Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials
American Journal of Preventive Cardiology · 2026-08 · 28 · 101659
DOI: 10.1016/j.ajpc.2026.101659 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Preventive Cardiology, 2026-08. Verfasst von Aditya Karthikeyan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, NY, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an established strategy to lower low-density lipoprotein cholesterol (LDL-C) and reduce atherosclerotic cardiovascular disease risk. Recently developed oral PCSK9 inhibitors may be a user-friendly alternative.
Methods
A systematic search from inception through March 6, 2026, identified randomized controlled trials comparing oral PCSK9 inhibitors with placebo in adults with established atherosclerotic cardiovascular disease or at high risk of atherosclerotic cardiovascular disease, receiving background lipid-lowering therapy, or with statin intolerance. The efficacy endpoint was percentage change in lipid levels including LDL-C, apolipoprotein-B, lipoprotein(a), triglycerides, and non-HDL-C. Safety outcomes included any adverse event, serious adverse events, discontinuation due to adverse events, and new-onset or worsening of diabetes attributed to intervention. Random-effects meta-analysis was performed using restricted-maximum-likelihood estimation with Hartung-Knapp-Sidik-Jonkman adjustment. Heterogeneity was assessed using I² statistic.
Results
Across five randomized phase 2 and 3 trials (n = 4226), oral PCSK9 inhibitors were associated with a significant reduction in LDL-C versus placebo (mean difference -49.92%; 95% CI -56.41 to -43.43; I² = 86%; PI, -72.30 to -27.54). Significant reductions were also observed in ApoB, Lp(a), triglycerides, and non-HDL-C. Safety outcomes were similar between both groups. In dose-matched analyses of MK-0616 at comparable dosing across trials, reductions in lipid markers remained significant with minimal heterogeneity.
Conclusions
Oral PCSK9 inhibitors were associated with reductions in LDL-C, ApoB, non-HDL-C, and lipoprotein(a), with safety profile comparable to placebo. Longer-term studies evaluating cardiovascular outcomes and comparisons with injectable PCSK9 inhibitors are required to define their clinical role.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, NY, USA.
- Division of Cardiology, Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Zitieren
APA
Karthikeyan, A., Karp, A., Maliha, M., Kharawala, A., Mangalesh, S., Shah, P., Modak, V., Alper, A., Doshi, A., Murli, H., Satish, V., Chi, K. Y., & Faillace, R. T. (2026). Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials. American Journal of Preventive Cardiology, 28, 101659. https://doi.org/10.1016/j.ajpc.2026.101659
Vancouver
Karthikeyan A, Karp A, Maliha M, Kharawala A, Mangalesh S, Shah P, et al. Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials. American Journal of Preventive Cardiology. 2026;28:101659. doi:10.1016/j.ajpc.2026.101659
BibTeX
@article{Karthikeyan2026,
author = {Karthikeyan, Aditya and Karp, Avrohom and Maliha, Maisha and Kharawala, Amrin and Mangalesh, Sridhar and Shah, Priyansh and Modak, Vishakha and Alper, Adir and Doshi, Apoorva and Murli, Hamsa and Satish, Vikyath and Chi, Kuan-Yu and Faillace, Robert T},
title = {Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials},
journal = {American Journal of Preventive Cardiology},
year = {2026},
volume = {28},
pages = {101659},
doi = {10.1016/j.ajpc.2026.101659}
}
EUVIMED